Advances and Perspectives in Prostate Cancer Biomarker Discovery in the Last 5 Years through Tissue and Urine Metabolomics

• Tipo: Outra Publicação em Revista Científica Internacional
• Data: 2021

Autores

Lima, AR (Autor) Outra; Pinto, J (Autor) Outra; Amaro, F (Autor) Outra; Maria de Lourdes Bastos (Autor) Outra; Carvalho, M (Autor) Outra; de Pinho, PG (Autor) FFUP

Revista

Título: Metabolites

Vol. 11

Página Final: 181

ISSN: 2218-1989

Editora: MDPI

Indexação

ISI Web of Knowledge - 35 Citações

Scopus - 36 Citações

Outras Informações

ID Authenticus: P-00T-Q2Y

DOI: 10.3390/metabo11030181

Abstract (EN): Prostate cancer (PCa) is the second most diagnosed cancer in men worldwide. For its screening, serum prostate specific antigen (PSA) test has been largely performed over the past decade, despite its lack of accuracy and inability to distinguish indolent from aggressive disease. Metabolomics has been widely applied in cancer biomarker discovery due to the well-known metabolic reprogramming characteristic of cancer cells. Most of the metabolomic studies have reported alterations in urine of PCa patients due its noninvasive collection, but the analysis of prostate tissue metabolome is an ideal approach to disclose specific modifications in PCa development. This review aims to summarize and discuss the most recent findings from tissue and urine metabolomic studies applied to PCa biomarker discovery. Eighteen metabolites were found consistently altered in PCa tissue among different studies, including alanine, arginine, uracil, glutamate, fumarate, and citrate. Urine metabolomic studies also showed consistency in the dysregulation of 15 metabolites and, interestingly, alterations in the levels of valine, taurine, leucine and citrate were found in common between urine and tissue studies. These findings unveil that the impact of PCa development in human metabolome may offer a promising strategy to find novel biomarkers for PCa diagnosis.

Idioma: Inglês

Tipo (Avaliação Docente): Científica

Nº de páginas: 28